公开(公告)号：US20200323850A1

公开(公告)日：2020-10-15

申请号：US16956860

申请日：2017-12-26

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Qingsong LIU ,  Jing LIU ,  Xiaofei LIANG ,  Beilei WANG ,  Kailin YU ,  Zongru JIANG ,  Cheng CHEN ,  Chen HU ,  Wenchao WANG ,  Fengming ZOU ,  Qingwang LIU ,  Feng LI ,  Wenliang WANG ,  Li WANG

IPC: A61K31/505 ,  A61P35/02 ,  C07D239/47 ,  C07D405/12 ,  A61K31/506 ,  C07D403/12 ,  C07D403/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  A61K31/5377

Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFRα and/or PDGFRβ kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.

公开(公告)号：US20210346406A1

公开(公告)日：2021-11-11

申请号：US17283646

申请日：2019-10-09

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Qingsong LIU ,  Jing LIU ,  Yun WU ,  Wenliang WANG ,  Beilei WANG ,  ZiPing QI ,  Junjie WANG ,  Wenchao WANG ,  Shuang QI ,  Li WANG

IPC: A61K31/635 ,  C07D475/00 ,  C07D475/12 ,  A61K31/519 ,  A61K31/5377 ,  A61P1/16 ,  A61P3/10

Abstract: Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.